News
In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results